- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT03406988
Autologous Adipose Tissue in the Treatment of Systemic Sclerosis Digital Ulcers (ADUL-SSc)
Regional Grafting of Autologous Adipose Tissue in the Treatment of Systemic Sclerosis Digital Ulcers: a Prospective Randomized Controlled Study
A randomized controlled trial will be performed to confirm preliminary uncontrolled data indicating that regional adipose tissue grafting is effective in inducing digital ulcer healing in patients with systemic sclerosis.
Systemic Sclerosis patients with digital ulcers will be randomized to be blindly treated with adipose tissue implantation or a sham procedure. Adipose tissue grafting will consist of injection at the base of the finger with digital ulcer of 0.5-1 ml of adipose tissue after centrifugation of fat aspirate. Sharm procedure will consist of false liposuction and local injection of saline solution.
The primary end-point will be to compare the cumulative prevalence of healed digital ulcers in the two groups within the following 8 weeks.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Systemic sclerosis (SSc) is an autoimmune disease characterized by a multifactorial pathological process where a central role is played by the progressive loss of the microvascular bed, with the consequent fibrotic changes in the involved organs and tissues.
The most advanced stages of capillary loss may induce the formation of digital ulcers (DUs) on the fingertips.The healing of DUs is often a lengthy process requiring accurate and intensive topical and systemic treatment. Nevertheless, in a significant number of cases this therapeutic approach is ineffective and distal necrosis with subsequent tissue loss or phalangeal amputation may eventually occur.
In a recent open pilot study performed by Del Papa et al., it has been demonstrated that autologous adipose tissue grafting (AT-G), which is known to contain both adipose-derived stem cells and a stromal/vascular fraction, was effective in inducing prompt healing of long lasting DUs localized in the fingertips of a small number of patients with SSc. The DU healing was accompanied by the rapid disappearance of local ischemic pain and evidence of a partial restoration of the capillary bed in the digits when assessed by nailfold videocapillaroscopy (NVC).
With the purpose of confirming these preliminary results, the investigators have designed a monocentric randomized controlled study. In accordance with the study protocol, patients with a typical SSc-related DU on the fingertip will be randomized to undergo a regional AT-G with autologous fat as active therapy or a 'sham' procedure (SP) - that simulates the active treatment - as placebo treatment. All of the patients with SSc enrolled in both arms will be blind regarding the treatment received. Furthermore, during the study period all of the enrolled patients will receive the same systemic vasoactive and topical therapy.
Type d'étude
Inscription (Anticipé)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
-
Milan, Italie, 20122
- Recrutement
- UOC Day Hospital Reumatologia, ASST G. Pini-CTO
-
Contact:
- Nicoletta Del Papa, MD
- Numéro de téléphone: +39-0258296415
- E-mail: nicoletta.delpapa@asst-pini-cto.it
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Patients candidate for enrollment in the study have to meet the 2013 classification criteria of the American College of Rheumatology/European League Against Rheumatism for SSc;
- Patients may have either the limited cutaneous or the diffuse cutaneous variants of SSc;
- All of the candidate patients must have only one active DU (cardinal ulcer), lasting for at least 6 weeks prior to enrolment time and showing no tendency to heal despite intravenous iloprost (0.5-2 ng/Kg/min), the oral administration of calcium-channel blockers (nifedipine) and local medication with surgical removal of necrotic tissue.
Exclusion Criteria:
- Presence of severe extra-cutaneous manifestations, such as cardiac, lung and renal involvement;
- Concomitant treatment with immune-suppressive therapies (including prednisone equivalent >10 mg);
- Current therapy with dual and selective endothelin inhibitors;
- Concomitant diabetes and/or other vascular diseases;
- Current pregnancy or breastfeeding.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Double
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Autologous fat grafting
Implantation of 0.5-1 ml of autologous AT at the base of the finger with DU.
|
Implantation of small amount of autologous adipose tissue at the base of the finger to induce a rapid healing of the distally located DU
Autres noms:
|
|
Comparateur placebo: Sham procedure
False liposuction followed by the injection of 0.5-1 ml of 0.9% saline solution at the base of the affected finger.
|
Local injection of 0.5ml saline solution after a simulated liposuction procedure.
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Digital Ulcer healing
Délai: 8 weeks after either autologus fat grafting or sham procedure.
|
Prevalence of DU healing in the arm treated with autologous fat grafting in comparison with the prevalence of healing in the placebo group.
|
8 weeks after either autologus fat grafting or sham procedure.
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Pain evaluation by Visual Analogue Scale (VAS)
Délai: This evaluation will be done at baseline and at the 2nd, 4th, 6th, 8th week after interventions (either autologus fat grafting or sham procedure).
|
The pain VAS is a continuous scale comprised of a horizontal line of 10 centimeters (100 mm) in length, ranging from 0 (minimum= no pain) to 100 (worst imaginable pain). The respondents will be asked to place a line perpendicular to the VAS line at the point that represents their pain intensity. Using a ruler, the score is determined by measuring the distance (mm) on the 10-cm line between the "no pain" anchor and the patient's mark, providing a range of scores from 0-100. In this study VAS score will be used to measure the decrease (or resolution) of pain with respect to baseline value in patients who will undergo treatment with autologous fat grafting (active arm) in comparison with patients of the placebo group. |
This evaluation will be done at baseline and at the 2nd, 4th, 6th, 8th week after interventions (either autologus fat grafting or sham procedure).
|
|
Neovascularization evaluation
Délai: Baseline and 8 weeks after either autologus fat grafting or sham procedure.
|
Increase of the number of capillaries assessed by NVC in the affected digit of patients treated with autologous fat grafting in comparison with patients of the placebo group.
|
Baseline and 8 weeks after either autologus fat grafting or sham procedure.
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chercheur principal: Nicoletta Del Papa, MD, ASST Gaetano Pini-CTO
Publications et liens utiles
Publications générales
- Gabrielli A, Avvedimento EV, Krieg T. Scleroderma. N Engl J Med. 2009 May 7;360(19):1989-2003. doi: 10.1056/NEJMra0806188. No abstract available.
- Steen V, Denton CP, Pope JE, Matucci-Cerinic M. Digital ulcers: overt vascular disease in systemic sclerosis. Rheumatology (Oxford). 2009 Jun;48 Suppl 3:iii19-24. doi: 10.1093/rheumatology/kep105.
- Del Papa N, Di Luca G, Sambataro D, Zaccara E, Maglione W, Gabrielli A, Fraticelli P, Moroncini G, Beretta L, Santaniello A, Sambataro G, Ferraresi R, Vitali C. Regional implantation of autologous adipose tissue-derived cells induces a prompt healing of long-lasting indolent digital ulcers in patients with systemic sclerosis. Cell Transplant. 2015;24(11):2297-305. doi: 10.3727/096368914X685636. Epub 2014 Dec 12.
- Del Papa N, Di Luca G, Andracco R, Zaccara E, Maglione W, Pignataro F, Minniti A, Vitali C. Regional grafting of autologous adipose tissue is effective in inducing prompt healing of indolent digital ulcers in patients with systemic sclerosis: results of a monocentric randomized controlled study. Arthritis Res Ther. 2019 Jan 7;21(1):7. doi: 10.1186/s13075-018-1792-8.
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Anticipé)
Achèvement de l'étude (Anticipé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Processus pathologiques
- Maladies de la peau
- Maladies du tissu conjonctif
- Sclérose
- Ulcère
- Sclérodermie systémique
- Sclérodermie diffuse
- Ulcère de la peau
- Effets physiologiques des médicaments
- Mécanismes moléculaires de l'action pharmacologique
- Agents vasodilatateurs
- Inhibiteurs de l'agrégation plaquettaire
- Modulateurs de transport membranaire
- Hormones et agents régulateurs du calcium
- Agents de contrôle de la reproduction
- Bloqueurs de canaux calciques
- Agents tocolytiques
- Iloprost
- Nifédipine
Autres numéros d'identification d'étude
- ID Sperimentazione 138
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Sclérodermie systémique
-
University of Alabama at BirminghamRésiliéLymphome anaplasique à grandes cellules | Lymphome T angio-immunoblastique | Lymphomes T périphériques | Leucémie à cellules T de l'adulte | Lymphome T adulte | Lymphome T périphérique Non précisé | T/Null Cell Systemic Type | Lymphome cutané à cellules T avec maladie nodale/viscéraleÉtats-Unis
Essais cliniques sur Autologous fat grafting
-
Washington University School of MedicineAbbVieRésiliéLymphome diffus à grandes cellules BÉtats-Unis
-
Klein Buendel, Inc.Pennington Biomedical Research CenterComplétéPrivation de sommeil | Surpoids et obésité | Comportement de santéÉtats-Unis
-
Riphah International UniversityRecrutement
-
NYU Langone HealthNational Institute on Deafness and Other Communication Disorders (NIDCD)RecrutementDéficience auditiveÉtats-Unis
-
University Hospital Southampton NHS Foundation...Boston Scientific Corporation; HeartFlow, Inc.; Wessex Heartbeat; CaristoRecrutementInfarctus du myocarde avec sus-décalage du segment STRoyaume-Uni
-
University of AarhusRanders Municipality, Denmark; Aarhus KommuneComplétéObésité pédiatriqueDanemark
-
Paul PoirierComplétéDiabète de type 2 | Réponse glycémiqueCanada
-
Malaysia Palm Oil BoardUniversiti Putra Malaysia; International Medical UniversityComplété
-
University of PennsylvaniaNational Heart, Lung, and Blood Institute (NHLBI); Arizona Pharmaceuticals...Complété
-
San Antonio Military Medical CenterComplété